LSA
TBPH icon

Leonteq Securities AG’s Theravance Biopharma TBPH Stock Holding History

Leonteq Securities AG’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28,726
Closed -$291K – 1356
2022
Q3 		$291K Hold
28,726
– – 0.01% 452
2022
Q2 		$260K Hold
28,726
– – 0.01% 507
2022
Q1 		$275K Buy
28,726
+19,126
+199% +$187K 0.01% 521
2021
Q4 		$106K Buy
9,600
+7,600
+380% +$66.2K ﹤0.01% 763
2021
Q3 		$14.8K Buy
+2,000
New +$22.4K ﹤0.01% 1025

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Leonteq Securities AG's TBPH Position: Q4 2022 in Review

Leonteq Securities AG sold out of Theravance Biopharma (TBPH) in Q4 2022, closing a stake of 28,726 shares — an estimated $291K sold.

Leonteq Securities AG first reported a position in TBPH in Q3 2021 and held it in 5 quarters. The position peaked at $291K in Q3 2022. 119 funds tracked by Wall St. Rank hold TBPH as of Q4 2022.

  • Leonteq Securities AG reported no remaining Theravance Biopharma position as of Q4 2022 after selling out during the quarter.
  • Leonteq Securities AG sold 28,726 Theravance Biopharma shares in Q4 2022, an estimated $291K.
  • Leonteq Securities AG first reported a position in Theravance Biopharma in Q3 2021 and held it in 5 quarters.
  • Leonteq Securities AG's Theravance Biopharma position peaked at $291K in Q3 2022.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2022.

Based on Leonteq Securities AG's 13F filing for Q4 2022, filed 26 Mar 2026.